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Introduction 
Since the introduction of first endoprosthesis in 1943 by 
Austin Moore, made of Vitallium (Chromium Cobalt Alloy), 
and the description of Total Femur Replacement by 
Buchanan in 1950, there had been a significant change in 
the management of extremity bone tumours in favour of 
limb salvage surgery.1,2 The introduction of 
chemotherapy particularly neo-adjuvant chemotherapy, 
the advances in surgical and diagnostic techniques, and 
the multidisciplinary approach allowed limb salvage 
procedures for sarcoma, with no obvious detectable 
differences in oncologic or functional results when 
compared with amputation.3,4 Hence, since 1980s, mega 
prosthesis had become the cornerstone of limb salvage 
surgeries, owing to their facilitation in early return to 
function, ability to bear weight, easy availability and 
better cosmetic appearance. Their use, in general, has 
drastically increased since the introduction of off-the-
shelf modular prosthesis instead of previously used 
custom prosthesis. It is due to all of these factors that the 
limb salvage surgery is now indicated in up to 90% of the 
musculoskeletal tumours.4  
In the light of these factors, there had been an evolution 
over the past three decades, in the biomedical 
engineering and refinement of surgical technique to 
enhance the oncological and functional outcome of 
endoprosthesis replacement which has, since then, 
become the primary modality of choice for limb salvage 
surgery.4,5 However, in the developing world, cost has 
been the most decisive limitation in the use of these 
implants. In a country where public has to pay for these 
services from their own resources, it becomes an 
expensive and unaffordable modality of choice and thus, 
presents a different kind of challenge.5 This is further 
aggravated by the non-availability of allograft in the 
country and absence of a bone bank. We are presenting 
our experience with functional outcome of mega endo-
prosthetic replacement over the past decade. A previous 
study was carried out by us in 2012, which has been the 
only work on mega-prosthetic replacement in Pakistan to 
this date.5 
Methods 
A retrospective study was conducted in the Aga Khan 
University Hospital, department. of Orthopaedics after 
ERC approval. All the patients diagnosed with malignant, 
benign and metastatic bone tumours were included. All 
paediatric and adult age group patients were considered 
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Abstract 
Objective: To evaluate the oncological and functional outcomes of bone tumour patients who underwent 
reconstruction with mega prosthesis. 
Methodology: A retrospective study was conducted in the department of Orthopaedics Aga Khan University 
Hospital, Karachi. All the paediatric and adult age group patients diagnosed with malignant, benign and metastatic 
bone tumours and meeting the inclusion criteria were selected and analysed.  Retrospective data was collected from 
January 2008-January 2018. 
Result: Sixty-two patients, 30 (48.4%) females and 32 (51.6%) males. were included in the study. Of these 57 (92%) 
cases had involvement of the lower limb. The mean age was 36.95±19.1 years with a range of 9-81 years. The 
duration of patients follow up was from 1-124 months (mean 32.7±36.43 months). There were 29 (47%) malignant 
cases. The most commonly occurring tumour site was distal femur and proximal femur. There were 53 (85%) primary 
surgeries (first time conducted surgeries) while 9(15%) revision surgeries were done. Major complications were 
encountered in 19 (30.6%) patients and 13 (20.9%) had minor complications. Post-surgery local recurrence occurred 
in 2 (3.2%) patients while 7 (11.2%) had distant metastasis. In functional outcomes the mean MSTS score of our 
patients was 72.09±26.43. The survival rate was 69.8% with 45 patients recovered. 
Conclusion: With a good patient selection, adherence to the principles of tumour surgery and an adequate applied 
knowledge of mega prosthesis insertion, a good functional outcome was achieved. 
Keywords: Bone neoplasm, Lower extremity, Femur, Recurrence. (JPMA 71: S-45 [Suppl. 5]; 2021)
eligible for inclusion in the study.  The medical records of 
patients from January 2008 to January 2018 were 
reviewed and the follow-up was taken till October 2018. 
There were 58 patients who were included in study. For 
assessing functional outcomes in treated patients, 
Musculoskeletal Tumour Society (MSTS) scoring system 
was used. This system assigns numerical values (0-5) for 
each of six categories: pain, and function and emotional 
acceptance in the upper and lower extremities; supports, 
and walking and gait in the lower extremity; and hand 
positioning, and dexterity and lifting ability in the upper 
extremity.6 These values were added, and the functional 
score was presented as a percentage of the maximum 
possible score. The results were graded according to the 
following scale: excellent 75-100%; good 70-74%; 
moderate 60-69%; fair 50-59 %; and poor 50 % based on 
our previous study.2 Post-surgery complications and 
patient's status either with local disease or metastatic 
disease were noted. Data was analyzed on statistical 
software SPSS version 22. Frequencies and descriptive 
statistic were calculated for categorical quantitative 
variables respectively. Chi2- Test was run for analyzing 
associations among variables and P-value < 0.05 was 
considered as significant for finding associations among 
variables. Kaplan-Meier test was used for calculating 
survival status of patients. 
Results 
The study included 62 patients, 30 (48.4%) females and 32 
(51.6%) males with an average age of 36.95±19.1 years 
(Range: 9-81 years) and a mean follow up of 32.71±36.43 
months (Range: 1-124 months). Regarding the nature of 
the tumour, 16 (25.4%) were benign while 29(47%) were 
malignant primary tumours, whereas, 17(27.4%) cases 
were of metastatic bone disease. Considering the 
presentation of the disease, 6(9.7%) 
were recurrence of the tumour while 
4(6.5%) were residual disease after 
marginal excision elsewhere. The 
remaining 52 (84.4%) cases belonged 
to the initial presentation group. The 
most frequent sites were proximal 
and distal femur, while there were 9 
(15.3%) cases of proximal tibia and 
5(8.5%) of proximal humerus. 
Regarding the nature of surgery, 53 
(85%) cases had primary surgery 
while 9(15%) were undergoing 
revision of a failed implant. In terms 
of implant type, 30 (48.4%) patients 
underwent distal femur mega endo-
prosthesis, 22(35.5%) had proximal 
femur replacement with hip 
arthroplasty, and 5(8%) had total femur replacement 
while 5 underwent proximal humerus replacement.  
Regarding oncological outcome, margins were negative 
in all primary bone tumours. Two patients had local 
recurrence while 7 had distant metastasis. Four patients 
were lost to follow up, however, they remained disease 
free till their last documented follow up.  
MSTS functional score was assessed in 34 patients, which 
gave a mean score of 72.09±26.43 (Range 27-100). 
Excellent outcome was achieved in 18, good outcome in 
6, fair in 5 while poor outcome was reported in 6 cases. 
There was an inverse relationship between age and MSTS 
score which was significant with p<0.01. No significant 
difference was found in the functional score of hip and 
knee surgery patients or secondary to difference in 
gender. 
Complications occurred in 32 patients with 19 having 
major complications which required prolonged hospital 
stay or readmissions, a second invasive intervention or a 
change in patient's functional status, while 13 patients 
had minor complications that required non-operative 
intervention without any change in functional status of 
J Pak Med Assoc (Suppl. 5)
34th International Pak OrthoCon Conference 2021 S-46
Table-1: Management of post-surgery complications. 
 
Variables                                                                       No. of Patients                 Percentage 
 
Non Operative                                                                              13                                          21 
Open/Closed Reduction                                                              6                                           9.6 
Wound Debridement                                                                  2                                           3.2 
Wound Debridement + Flap Coverage                                 4                                           6.4 
Revision                                                                                           3                                           4.8 
Amputation                                                                                    3                                           4.8 
Others                                                                                               2                                           3.2
Figure-1: Types of post-surgery major complications. DVT: Deep Vein Thrombosis
the patients. Major complications included deep 
infections, dislocation, aseptic loosening, soft tissue 
failure, neurovascular damage and local recurrence 
(Figure-1). For management of complications, 6 required 
open or closed reduction, 6 had wound debridement with 
4 of them requiring additional flap coverage. Three 
patients needed revision surgery while three more ended 
up having amputation. One patient required tendon 
transfers for radial nerve injury (Table-1). 
Out of the 62 patients, 17 expired thus the survival rate 
was 69.8%. Mean survival time was 76.3 months with 
standard error of 8.55. Survival rate of primary malignant 
bone tumours was 80% (Figure-2). 
Discussion 
The mean MSTS score was 72.09% and 52% patients had 
some complications in the presented study. A major 
complication was seen in 31% patients requiring a second 
invasive intervention or lead to a change in functional 
status. These included wound dehiscence, deep tissue 
infection, major neurovascular damage, aseptic loosening 
or dislocation. Minor complications as delayed wound 
healing, cellulitis and superficial infection requiring 
antibiotics therapy was encountered in 21% patients.  Our 
mean functional score was comparable to our previous 
study.2 However, it remained lower than Tan et al. and 
Tunn et al. which were 78% and 77% respectively.7,8  
Custom built prosthesis were introduced 
in 1949 initially by Stanmore, however, 
they gained popularity in 1970s because 
of the advent of neo-adjuvant 
chemotherapy and advancements in 
diagnostic modalities. Over the next 
decade, introduction of modular 
prosthesis ensured not only the easy 
availability and cheaper cost but also 
more flexibility during resection.7 
Moreover, though these implants have 
been introduced primarily for oncological 
indications but they have also been of 
paramount utilization in the event of 
revision surgeries with large osseous 
defects, aseptic loosening, peri-prosthetic 
fractures and pseudo-arthrosis.9  
These custom prosthesis used to replace 
the femur, the hip joint, part of the pelvis, 
the knee joint, the humerus and shoulder 
joint, and parts of the ulna and radius 
which are the most common predilection 
sites of primary bone tumours.10 In 
addition to these, custom and modular 
implants have also been involved in management of 
metastatic bone disease particularly in the setting of a 
pathological fracture and wherever the intent is 
palliative.11,12 The most usual site, in case of metastatic 
disease, has been proximal femur.12 
Mega-prosthetic reconstruction has many advantages. 
The load-bearing characteristics of prosthetic 
reconstruction surgery offer immediate postoperative 
stability and facilitate rapid rehabilitation. However, 
appropriate patient selection is paramount to obtain 
better and more consistent results. The involvement of 
major structures is considered an important factor in 
determination of limb salvage vs amputation. The 
decision is to be made once patients are re-evaluated 
after the neo-adjuvant treatment, through which, some 
patients who are not candidates of limb salvage initially, 
may experience shrinkage in tumour size and thus 
increase in chances of limb salvage. Another patient 
group is the one with poor prognostic factors like 
metastasis on presentation, bone metastatic disease and 
ineffective response to chemotherapy. Mega endo-
prosthetic reconstruction is a viable option in such 
patients to improve quality of life when compared to 
debilitating radical management, wherever there is a 
limited life expectancy.13  
Endo-prosthetic reconstruction has now comparable 
results with amputation regarding oncological outcome 
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Figure-2: Survival curve of patients with regard to nature of tumor.
and long-term survival but also with better functional 
outcome in terms of Musculoskeletal Tumour Society 
(MSTS) score. Since, bone sarcomas are the fourth most 
common cancer in individuals under the age of 25, this 
demands longevity of the reconstructions. Furthermore, 
cancer patients are more prone to complications, due to 
the impaired immune system, longer surgery time, and 
greater loss of tissue and structures.14 These mega-
prosthesis also have worse long-term results compared to 
conventional total joint replacements.15 
Nevertheless, all of these studies were based on primary 
bone tumours while our work also incorporated the cases 
of metastatic bone disease. In terms of functional 
outcomes, deep infection and concomitant pathology 
e.g., advanced osteoarthritis or AVN of ipsilateral joints 
also has an influence.15,16 Comparison with other studies 
in literature is displayed in Table-2. 
On comparison with other studies17-19 with the rates of 4% to 
30%, 9.6% of our patients showed peri-prosthetic infection 
which is one of the most common complication after mega 
endo-prosthesis apart from local recurrence (Figure-3A). This 
is attributed to various risk factors like tumour disease, 
chemotherapy-induced immunosuppression, poor soft 
tissue situation due to radiation therapy, long operation time 
and inadequacy of coverage.20 One patient with 
metastatic renal carcinoma underwent tumour debulking 
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Table-2: Comparison of our surgical and functional outcomes with international literature. 
 
Author                                                No. of                                        Type of                                        MSTS                           Aseptic Loosening /                              Implant                              Infection 
                                                               cases                                      prosthesis                                       (%)                                  Dislocation (%)                              fracture (%)                               (%) 
 
Qadir et. al.2                                           16                                                 Mix                                               72.3                                              12.5                                                       0                                           12.5 
Malawer et. al.6                                     68                                                 Mix                                                 75                                                  17                                                         0                                             13 
Tan et. al.7                                               19                                                 Mix                                               78.3                                              10.5                                                       0                                           31.5 
Natarajan et. al.16                                 17                                         Total Femur                                       66.6                                              11.8                                                       0                                           11.8 
Futani et al.26                                         22                                        Distal Femur                                        74                                                22.7                                                     9.1                                          27.3 
Current Series                                        62                                                 Mix                                               72.1                                               4.9                                                        0                                             9.6
Figure-3A: Patient developed deep infection and wound dehiscence. Flap coverage 
was attempted twice which failed.
Figure-3B: X-ray showing inadequate cement mantle causing aseptic loosening.
and proximal femur replacement while four with primary 
malignant bone tumours received neo-adjuvant as well as 
adjuvant chemotherapy. Another case was that of a 14 
year old girl with Ewing's Sarcoma who developed peri-
prosthetic infection after 5 years of index surgery, though 
in literature, majority of the cases present within first two 
years.20 No significant difference was found in the 
infection rate between hip and knee surgeries. Recent 
studies have shown the promising results of silver coated 
mega-endoprosthesis in terms of decreased infection 
rate, however, no long-term level 1 data is available yet. 
Moreover, cost and availability have also been major 
deterrents of those implants in our setting.21,22 
Three amputations had been observed in our study in 
which 2 of them had infection and patients underwent 
multiple wound debridement and coverage. In the third 
case, however, there was recurrence after undergoing 
intramedullary nailing of the pathological fracture of 
femur secondary to a Leiomyosarcoma, which was found 
out on subsequent biopsy. Our overall limb salvage rate 
was 95%. 
Among the patients who required revision surgery, we 
performed revision of femoral components only. Both 
remained disease free, however, one of them developed 
coronal instability after 10 years of initial surgery (Figure-
3B). One of the rare complications and cause of revision is 
failure of hinge mechanism, which was also experienced 
by one of our patients. He eventually developed knee 
dislocation. Polyethylene (PE) bushing failure had been 
the likely mechanism in our case, which is also reported as 
one of the reasons of this type of failure.23 
Our recurrence rate in primary malignancies remained 9% 
which is comparable with literature. Both Ham et al. and 
Malawer et al. reported 6% rate of local recurrence.6, 24 
Overall survival rate of our patients was 67.8%, whereas, 
mean survival time was 76±8.55 months. These were 
primarily patients with metastatic bone disease. Among 
those with primary malignant bone tumours, survival rate 
had been 80%. 
Conclusion 
Mega-endoprosthetic reconstruction is a good option, in 
terms of functional outcome, for limb salvage after bone 
tumour resection, with an acceptable rate of 
complications. However, cost has been a major deterrent. 
Patient selection and rehabilitation is of paramount 
importance for a good outcome. 
Limitations 
There were numerous limitations in our study. Most 
important one was the small sample size despite a long 
span of 10 years. This is because of the financial 
limitations of our patient group. Secondly, we used 
prosthesis from different providers, which may have a 
bearing upon mechanical complications and long-term 
survival of the implants. However, it had no bearing upon 
resection plan and margins. Moreover, the follow up is too 
short in some cases to have any implications upon 
recurrence rate, functional score and particularly survival. 
Recommendations 
Future refinements in technique and technology would 
certainly improve the outcome and minimize the 
complications associated with limb salvage. 
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